FS Development Corp. II
FSII
NASDAQ Global Select9.80
USD
-0.20
- -
CIK
0001822711
ISIN
US30318F1003
CUSIP
30318F100
Return %
Stock
S&P500
1Y
- -
18.21
3Y
-9.18
64.38
5Y
-9.18
72.43
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 600 Montgomery Street San Francisco CA United States of America 94111
- IPO Date
- Feb 17, 2021
- CIK
- 0001822711
- Similar Companies
- Business
- FS Development Corp. II is a special purpose acquisition company (SPAC) primarily focused on mergers and acquisitions in the biopharmaceutical sector. It plays an active role in sponsoring business combinations with clinical-stage biotechnology firms. The company is known for its involvement in the merger with Pardes Biosciences, a clinical-stage biopharmaceutical company developing PBI-0451, an oral antiviral drug candidate aimed at treating and preventing SARS-CoV-2 infections. This merger represented a significant strategic move, transforming FS Development Corp. II into a publicly traded biopharmaceutical company under the name Pardes Biosciences, Inc., with shares traded on the Nasdaq Global Market under the ticker symbol PRDS. FS Development Corp. II’s core business involves facilitating capital formation and strategic partnerships for emerging biotech firms, assisting in advancing innovative therapeutic candidates through public market access. The company’s primary product focus post-merger includes oral antiviral therapeutics targeting infectious diseases such as COVID-19, leveraging Pardes Biosciences’ tunable, reversible covalent chemistry platform. It operates mainly within the United States healthcare and biotechnology industry with a strategic emphasis on antiviral drug development. Recent major company changes include the consummation of the business combination with Pardes Biosciences in December 2021, which involved a substantial PIPE financing transaction aggregating approximately $276 million of gross proceeds aimed at advancing Pardes’ lead antiviral drug candidate. This transaction reflects FS Development Corp. II’s strategic shift from a blank-check acquisition vehicle to an operational biopharmaceutical entity with a dedicated drug development pipeline. The company is sponsored by Foresite Capital and prominently supported by investors such as Foresite Capital Opportunity Fund and Khosla Ventures. Founded as a Delaware corporation, FS Development Corp. II is headquartered in San Francisco, California. It operates under the governance of sponsors and stakeholders with expertise in biotech investment and development. The company’s evolution from a SPAC to a biotech operating company underscores its mission to facilitate innovation and growth in specialized pharmaceutical markets. In summary, FS Development Corp. II transitioned from a SPAC vehicle into Pardes Biosciences, focusing on oral antiviral drug development for infectious diseases, underpinned by a significant merger that expanded its operational scope and capital base in the biopharmaceutical industry. This positions the company as a specialized player advancing novel therapeutic candidates with public market support and strategic investor backing.
Pardes Biosciences and FS Development Corp. II Announce Merger Agreement Creating Publicly Listed Biopharmaceutical Company Advancing Oral Antiviral Drugs to Treat and Prevent SARS-CoV-2 Infections
2 New Healthcare SPACs Worth Adding to Your Watch List
U.S. IPO Weekly Recap: The IPO Market Takes Its Annual February Break In A 1 IPO Week
FS Development Corp. II, Sponsored by Foresite Capital, Announces Pricing of Upsized $175 Million Initial Public Offering